Sickle cell disease is a group of inherited red blood cell disorders caused by abnormal hemoglobin. Red blood cells become rigid and sickle-shaped, leading to vaso-occlusion, pain crises, hemolysis, and organ damage.
Canaccord Genuity initiated Beam Therapeutics with a buy rating and $74 price target, highlighting near-term catalysts. Beam reached an agreement with the FDA on an accelerated approval pathway for its BEAM-302 AATD therapy, which showed early clinical proof-of-concept for in vivo base editing. The company plans a BLA for risto-cel and a pivotal plan for BEAM-302 in early 2026.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.
More than 30 approved cell and gene therapies carry prices from nearly $1 million to over $4 million, creating fiscal pressure for Medicaid. A federal access model launched in 2024 aims to centralize outcomes-based contracting.
Transformative therapies including stem cell transplant and gene therapy offer sickle cell disease patients potential freedom from the SCD phenotype with reduced morbidities. About 90% of patients successfully switch to donor blood cell production after transplant, while gene therapies work by editing the patient's own stem cells. These treatments require careful consideration of disease severity and potential risks including major adverse events.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The cell therapy manufacturing market is projected to reach $14.01 billion by 2035, with CAR-T therapies dominating at 65% market share. Recent FDA approvals for new CAR-T indications and Japanese regulatory acceleration highlight growing clinical adoption, while research advances include new anti-aging protein platforms and CRISPR-based treatments.
Scientists have developed two breakthrough approaches to dramatically enhance gene editing and mRNA therapy delivery: a simple amino acid supplement that increases CRISPR efficiency to nearly 90 percent, and a self-replicating CRISPR system that spreads between cells like a virus.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07616154 |
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07610239 |
Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening |
RECRUITING | NA |
| NCT07599176 |
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors |
RECRUITING | PHASE1/PHASE2 |
| NCT07562451 |
Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing |
NOT_YET_RECRUITING | NA |
| NCT07554547 |
Crizanlizumab Pregnancy Outcomes Intensive Monitoring |
COMPLETED | |
| NCT07543289 |
Hydroxyurea Optimisation in Sickle Cell Disease |
NOT_YET_RECRUITING | |
| NCT07540767 |
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease |
NOT_YET_RECRUITING | NA |
| NCT07498309 |
Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07450430 |
Optimal Timing of Ketamine Initiation for SCD Pain |
NOT_YET_RECRUITING | PHASE3 |
| NCT07442851 |
SickleFit Exercise and Nutrition Study |
RECRUITING | NA |
